Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 51,135 shares of the company’s stock, valued at approximately $2,601,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in Ionis Pharmaceuticals by 2.1% during the first quarter. FMR LLC now owns 18,562,420 shares of the company’s stock valued at $746,210,000 after acquiring an additional 381,975 shares during the period. Vanguard Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 4.3% in the first quarter. Vanguard Group Inc. now owns 9,437,796 shares of the company’s stock worth $379,399,000 after purchasing an additional 384,830 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Ionis Pharmaceuticals by 56.1% in the first quarter. Wellington Management Group LLP now owns 9,360,553 shares of the company’s stock worth $376,295,000 after purchasing an additional 3,364,621 shares during the last quarter. BB Biotech AG increased its holdings in shares of Ionis Pharmaceuticals by 7.9% in the first quarter. BB Biotech AG now owns 7,461,295 shares of the company’s stock worth $299,944,000 after purchasing an additional 548,123 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Ionis Pharmaceuticals by 37,569.7% in the first quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock worth $263,704,000 after purchasing an additional 6,542,394 shares during the last quarter. Institutional investors own 89.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Los Angeles Capital Management & Equity Research Inc. Buys New Stake in Ionis Pharmaceuticals, Inc. (IONS)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/15/los-angeles-capital-management-equity-research-inc-buys-new-stake-in-ionis-pharmaceuticals-inc-ions.html.

In other news, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were acquired at an average price of $8.00 per share, with a total value of $25,000,000.00. Following the acquisition, the insider now directly owns 28,884,540 shares in the company, valued at $231,076,320. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Patrick R. O’neil sold 1,000 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $55.00, for a total transaction of $55,000.00. Following the completion of the sale, the senior vice president now directly owns 10,633 shares in the company, valued at approximately $584,815. The disclosure for this sale can be found here. Insiders sold 55,309 shares of company stock valued at $2,997,692 over the last 90 days. Insiders own 1.86% of the company’s stock.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at 58.34 on Friday. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.58 and a 52-week high of $60.01. The company’s 50 day moving average is $51.14 and its 200-day moving average is $48.01. The stock has a market cap of $7.25 billion, a PE ratio of 280.48 and a beta of 3.13.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. Ionis Pharmaceuticals’s revenue was up 170.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.47) EPS. On average, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current year.

IONS has been the topic of several analyst reports. TheStreet raised Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. BMO Capital Markets restated a “buy” rating and set a $59.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, June 2nd. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research report on Wednesday, July 12th. Cowen and Company restated a “market perform” rating on shares of Ionis Pharmaceuticals in a research report on Monday, May 22nd. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $42.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, July 10th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. Ionis Pharmaceuticals has an average rating of “Hold” and an average target price of $49.31.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.